On 30 June, the members of the Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) project announced the completion of the last patient visit in its Prognostic and Natural History Study (PNHS). All sites have been done with the recruitment and scanning of participants, which represents an important milestone. The PNHS study is an open-label, prospective and multi-centre cohort study aiming to understand the role of amyloid PET imaging in the earliest stages of Alzheimer’s disease (AD). The first participant was recruited in Amsterdam, The Netherlands, in October 2018. The study succeeded in recruiting 1,321 participants. The final scans were performed in June and the number of prospective scans collected within AMYPAD PNHS is 1,419 (1,192 baseline and 227 follow-up). At this moment, the AMYPAD team is focused on the close out of the sites and the last closure visit is scheduled for September 2022. The AMYPAD project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. The Joint Undertaking receives support from the European Union’s Horizon2020 research and innovation programme and EFPIA.
AMYPAD completes the last patient visit in its Prognostic and Natural History Study